Author: Scavone, Cristina; Brusco, Simona; Bertini, Michele; Sportiello, Liberata; Rafaniello, Concetta; Zoccoli, Alice; Berrino, Liberato; Racagni, Giorgio; Rossi, Francesco; Capuano, Annalisa
Title: Current pharmacological treatments for COVIDâ€19: What's next? Cord-id: gsoxaso9 Document date: 2020_5_15
ID: gsoxaso9
Snippet: Since December 2019 SARSâ€Covâ€2 was found responsible for the disease COVIDâ€19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVIDâ€19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVIDâ€19, focusing on their antiviral, immuneâ
Document: Since December 2019 SARSâ€Covâ€2 was found responsible for the disease COVIDâ€19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVIDâ€19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVIDâ€19, focusing on their antiviral, immuneâ€modulatory and/or antiâ€inflammatory actions. Where available, data from clinical trials involving patients with COVIDâ€19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVIDâ€19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVIDâ€19 and reducing its symptoms and complications.
Search related documents:
Co phrase search for related documents- action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and adjunctive therapy: 1, 2
- action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and lopinavir ritonavir treatment: 1, 2
- action mechanism and lung damage: 1, 2, 3, 4, 5, 6
- action mechanism and lymphocyte count: 1, 2
- acute ards respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and liver impairment: 1
- acute ards respiratory distress syndrome and long medium: 1, 2
- acute ards respiratory distress syndrome and long medium term: 1
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and low lymphocyte count: 1, 2
- acute ards respiratory distress syndrome and lung complication: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute ards respiratory distress syndrome and lung parenchyma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
Co phrase search for related documents, hyperlinks ordered by date